Neural Regeneration Research

: 2021  |  Volume : 16  |  Issue : 2  |  Page : 205--213

Role of apoptosis-inducing factor in perinatal hypoxic-ischemic brain injury

Juan Rodriguez1, Tao Li2, Yiran Xu2, Yanyan Sun3, Changlian Zhu4,  
1 Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Henan Key Laboratory of Child Brain Injury, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China;
3 Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Anatomy, School of Basic Medical Science, Zhengzhou University, Zhengzhou, Henan Province, China
4 Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Henan Key Laboratory of Child Brain Injury, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

Correspondence Address:
Changlian Zhu
Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Henan Key Laboratory of Child Brain Injury, Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden


Perinatal complications, such as asphyxia, can cause brain injuries that are often associated with subsequent neurological deficits, such as cerebral palsy or mental retardation. The mechanisms of perinatal brain injury are not fully understood, but mitochondria play a prominent role not only due to their central function in metabolism but also because many proteins with apoptosis-related functions are located in the mitochondrion. Among these proteins, apoptosis-inducing factor has already been shown to be an important factor involved in neuronal cell death upon hypoxia-ischemia, but a better understanding of the mechanisms behind these processes is required for the development of more effective treatments during the early stages of perinatal brain injury. In this review, we focus on the molecular mechanisms of hypoxic-ischemic encephalopathy, specifically on the importance of apoptosis-inducing factor. The relevance of apoptosis-inducing factor is based not only because it participates in the caspase-independent apoptotic pathway but also because it plays a crucial role in mitochondrial energetic functionality, especially with regard to the maintenance of electron transport during oxidative phosphorylation and in oxidative stress, acting as a free radical scavenger. We also discuss all the different apoptosis-inducing factor isoforms discovered, focusing especially on apoptosis-inducing factor 2, which is only expressed in the brain and the functions of which are starting now to be clarified. Finally, we summarized the interaction of apoptosis-inducing factor with several proteins that are crucial for both apoptosis-inducing factor functions (pro-survival and pro-apoptotic) and that are highly important in order to develop promising therapeutic targets for improving outcomes after perinatal brain injury.

How to cite this article:
Rodriguez J, Li T, Xu Y, Sun Y, Zhu C. Role of apoptosis-inducing factor in perinatal hypoxic-ischemic brain injury.Neural Regen Res 2021;16:205-213

How to cite this URL:
Rodriguez J, Li T, Xu Y, Sun Y, Zhu C. Role of apoptosis-inducing factor in perinatal hypoxic-ischemic brain injury. Neural Regen Res [serial online] 2021 [cited 2020 Oct 20 ];16:205-213
Available from:

Full Text


Perinatal brain injury is a major public health issue and is a leading cause of neonatal mortality and morbidity (Liu et al., 2016). It may lead to developmental impairment and permanent neurological deficits, such as cerebral palsy and mental retardation (Lally et al., 2019; Juul et al., 2020). Among many etiological factors, hypoxic-ischemic encephalopathy (HIE) in term infants and intraventricular/periventricular hemorrhage in preterm infants are the most common causes of perinatal brain damage (Hagberg et al., 2015). The different etiological factors during critical developmental periods can lead to a common pathway of perinatal brain injury marked by neuronal excitotoxicity, cellular apoptosis, and microglial activation (Hagberg et al., 2014; Wu et al., 2019). Apoptosis has been found more prominent in the immature brain compared to the mature brain (Zhu et al., 2005). Some clinical studies have shown promising results for perinatal brain injury (Zhu et al., 2009a; Azzopardi et al., 2016); however, widely accepted clinically efficient therapy is still limited (Tagin et al., 2015; Hagberg et al., 2016). Thus, there is a pressing need for a better understanding of the mechanisms of neuronal cell death and perinatal brain injury and for conducting comparative and translational studies on how to reduce neuronal cell death, increase cell survival, and promote brain regeneration and repair after injury. Perinatal hypoxia-ischemia (HI)-induced brain injury is one of the most common forms of neonatal brain injury, which is more common in the developing countries (Liu et al., 2016). Thus, we focus on the molecular mechanisms of hypoxic-ischemic brain injury in this review, specifically the importance of apoptosis-inducing factor (AIF) as a key protein for finding new therapeutic strategies for preventing perinatal brain injury.

An electronic search of the Google Scholar and PubMed for literature describing apoptosis-inducing factor in perinatal hypoxic-ischemic brain injury from 1996 to 2020 was performed using the following conditions: (AIF [All Fields] OR “apoptosis-inducing factor”[All Fields]) NOT (“neoplasms”[MeSH Terms] OR “neoplasms”[All Fields] OR “cancer”[All Fields]).

 Clinical Consequence of Hypoxic-Ischemic Encephalopathy

HIE is a condition that is associated with oxygen deprivation in the neonate due to perinatal asphyxia. Despite important progress in neonatal care over the last decades, HIE is still an important contributor to neonatal mortality and to major neurodevelopmental disabilities, including mental retardation, cerebral palsy, learning disabilities, and seizures (Van Handel et al., 2007; Douglas-Escobar and Weiss, 2015; Yıldız et al., 2017; Schreglmann et al., 2020). Due to improvements in perinatal care and the increased survival rate of infants born with a low gestational age, the absolute number of subjects affected by these complications has increased. The incidence of HIE ranges from 1 to 8 per 1000 live births in developed countries, but underdeveloped countries have reported incidences of up to 26 per 1000 live births (Hayakawa et al., 2014; Douglas-Escobar and Weiss, 2015). Hypoxic-ischemic brain injury can occur in newborns at any gestational age, but preterm and very preterm babies are less prepared to adapt to perinatal insults compared to term infants, making them more vulnerable to neurodevelopmental impairments due to hypoxia-ischemia (HI; Gopagondanahalli et al., 2016). Although premature babies are able to tolerate more prolonged periods of HI, the effect can dramatically alter the normal development of the immature brain (Bennet et al., 2013; Galinsky et al., 2018). HIE can be ranked in three clinical stages according to the widely accepted Sarnat scoring system as mild, moderate, and severe encephalopathy (Sarnat and Sarnat, 1976). The few infants who survive severe HIE will most likely develop life-long complications (Hankins and Speer, 2003), while for moderate HIE, some estimations suggest that about 30–40% of the survivors develop cerebral palsy or other major neurological impairments and another 30–40% develop cognitive problems (Lindström et al., 2006). Other studies have shown that untreated moderate to severe HIE results in an approximately 60% risk of either death or major neurological impairments, which is a major burden to those afflicted, their families, and society (Carli et al., 2004; Edwards et al., 2010; Natarajan et al., 2016).

 Mechanisms of Hypoxic-Ischemic Brain Injury

Asphyxia in newborn infants causes brain injury that lasts for several days due to mechanisms of cellular apoptosis, autophagy, necrosis, and inflammation, and mitochondria play extremely important roles in these processes (Xie et al., 2016; Hua et al., 2017; Thornton et al., 2017; Li et al., 2019). The type of cell death depends on several factors, including the severity of the insult, the cell type, the metabolic stress, the sex of the infant, and the elapsed time since the event (Demarest et al., 2016; Thornton et al., 2017; Charriaut-Marlangue et al., 2018). Apoptosis is a physiological process during normal brain development, whereby cells are discretely removed. Studies have shown that apoptotic cell death machinery is activated in pathological conditions, such as HI, and apoptosis is much more prominent in the immature brain.


Two main apoptotic pathways occur in the cell: the extrinsic pathway mediated by death receptors and the intrinsic pathway mediated by the mitochondria (Thornton et al., 2017). Both routes take place through multiple molecular mechanisms and are related to each other, such that the molecular events of one influence the other. Contrary to the extrinsic pathway (which is triggered by extracellular signals that oligomerize death receptors located on the plasma membrane (Wajant, 2002)), the intrinsic pathway is triggered by intracellular stimuli, such as an increase of reactive oxygen species, nitric oxide, and Ca2+ caused by glutamate overflow (Hagberg et al., 2014; Sutcliffe et al., 2017). The extrinsic pathway activates BID protein (a pro-apoptotic B-cell lymphoma 2, BCL-2 family member, also known as BH3 interacting-domain death agonist), which in turn oligomerize BCL-2-associated X protein and BCL-2 homologous antagonist killer 1 (BAK1) (Korsmeyer et al., 2000; Wang et al., 2010). These proteins play a crucial role in mitochondrial outer membrane permeabilization (MOMP) and pore formation (Zhu et al., 2010; Shamas-Din et al., 2011; Green and Llambi, 2015; Stehle et al., 2018). Subsequently, the release from the mitochondria to the cytosol of pro-apoptotic proteins will occur, including cytochrome c (Cyt c), AIF, second mitochondria-derived activator of caspases, and endonuclease G (Thornton et al., 2017), making this a crucial event for another way to classify apoptosis, depending on the final executor, and that differ in their dependence or independence on cysteine-aspartic proteases (caspases). Caspase-dependent apoptosis is initiated by Cyt c and the subsequent assembly of the apoptosome complex in the cytosol. This event will lead to the activation of caspase 3, which will cut the DNA into small pieces of about 200 to 1000 bp (Jänicke et al., 1998). The caspase-independent pathway terminates with the translocation of AIF (also known as “parthanatos”) to the nucleus mainly, where it will cause large-scale DNA fragmentation (into pieces of about 50,000 bp) and chromatin condensation (Galluzzi et al., 2009; Fatokun et al., 2014).

Apoptosis is a crucial process in the immature brain, and it determines the appropriate development of the central nervous system. Unsurprisingly, many components of the intrinsic pathway, as well as proteins involved in apoptosis (such as caspase 3, BCL-2 family proteins, and AIF) are upregulated during brain development (Thornton et al., 2017). Indeed, these apoptotic mechanisms, including nuclear translocation of AIF, Cyt c release, and caspase 3 activation, have been found to be more prominent in immature than in juvenile and adult mouse brains (Zhu et al., 2005).

Apoptosis-inducing factor

AIF (full gene name: apoptosis-inducing factor, mitochondria-associated 1; AIFM1) is a flavin adenine dinucleotide (FAD)-dependent, nicotinamide adenine dinucleotide (NAD+) oxidoreductase that is located in the mitochondrial intermembrane space under physiological conditions (Candé et al., 2002). AIF is a highly conserved protein, and it has significant homology with the oxidoreductases of bacteria, plants, and fungi (Elguindy and Nakamaru-Ogiso, 2015). In humans, the gene encoding AIF is located at the q26.1 region of the X chromosome. The most abundant transcript, called AIFM1 (Gene ID: 9131), possesses a transcribed region encoded in 16 exons that generates a 67 kDa precursor molecule of 613 amino acids (AAs) in humans (Susin et al., 1999b). AIF1 has three domains: FAD-bipartite binding domain (AAs 129–262 and AAs 401–480), a NADH-binding motif (AAs 263–400), and a C-terminal domain (AAs 481–608) (Lorenzo et al., 1999). In addition, there are two mitochondrial localization sequences (MLSs) placed one after the other in the N-terminal region (AAs 1–41) and two nuclear localization sequences (NLS1 and NLS2) located within the two FAD-binding domains (Porter and Urbano, 2006). The MLS drives the transportation of AIF into the mitochondrial intermembrane space (Susin et al., 1996; Zamzami et al., 1996). Once there, AIF will undergo the first proteolytic cleavage and thus be processed to a mature form (62 kDa) [Figure 1]. AIF is then inserted through its amino-terminal transmembrane segment into the inner mitochondrial membrane (IMM), leaving the rest of the protein exposed to the mitochondrial intermembrane space (Otera et al., 2005). The amino-terminal transmembrane domain (TMD) encompasses AAs 54 (where the mitochondrial-processing peptidase cleavage site is located) to 103 (where the calpain/cathepsin cleavage site is located). Within the amino-terminal transmembrane segment is the TMD (AAs 67–83). AIF also has two binding domains: one for heat shock protein 70 (HSP70) at AAs 150–228 (included in the FAD-binding domain), another for cyclophilin A (CypA) at AAs 367–399 (included in the NADH-binding motif), and the last one for macrophage migration inhibitory factor (MIF) at AAs 567–592. AIF also possesses two DNA-binding sites located in AAs 255–265 and 510–518 [Figure 1].{Figure 1}

In the absence of apoptotic stimuli, AIF is essential for obtaining energy in the mitochondria, as well as for the optimal functioning of the respiratory chain (Vahsen et al., 2004), making AIF an essential protein for survival (Joza et al., 2001). AIF involvement in free radical formation and removal has also been suggested (Klein et al., 2002; Ishimura et al., 2008). In addition, some studies have suggested a relationship between AIF’s redox function with the biogenesis and/or assembly of complexes I and III of the electron transport chain during oxidative phosphorylation (OxPhos), as well as with the maintenance of these complexes for optimal performance (Fato et al., 2008; Hangen et al., 2010a). Interestingly, in vitro studies have shown that AIF depletion by AIF siRNA in a model system of glutamate toxicity in immortalized hippocampal HT-22 neurons had effects similar to rotenone, a specific mitochondrial complex I inhibitor, thus mediating a preconditioning effect at the level of the mitochondria (Öxler et al., 2012).

In the presence of apoptotic stimuli, AIF plays a central role in neuronal cell death (Kroemer et al., 2007; Hagberg et al., 2014). In 2003, we found that AIF was involved in neuronal cell death after HI in the neonatal rat brain (Zhu et al., 2003). AIF was detected in the nuclei just a few hours after HI and only in damaged areas. Furthermore, the larger the infarct volume was, the greater the number of AIF-positive nuclei were found and treating the mice with a multi-caspase inhibitor did not alter the number of AIF-positive nuclei (Susin et al., 1999a; Zhu et al., 2003). We know now that, after HI, AIF is cleaved from the IMM by calpains and/or cathepsins in its apoptotic form [Figure 1] (Polster et al., 2005; Yuste et al., 2005), with a molecular weight of 57 kDa (Otera et al., 2005). The protein refolds while incorporating FAD and is then released into the cytosol, where it combines with CypA. After this, the complex translocates to the nucleus (Zhu et al., 2007a). Artus et al. (2010) subsequently found that, once in the nucleus, AIF also interacts with H2A histone family member X (H2AX). H2AX is linked to DNA damage repair by modifying the chromatin structure and making damaged DNA sites accessible to repair factors (Paull et al., 2000). The AIF/H2AX complex improves DNA’s accessibility to AIF (Cande et al., 2004), thus making the synchronized presence of these three proteins a team with specialized roles: AIF (binding domains), H2AX (generation of DNA accessibility), and CypA (DNase activity) (Artus et al., 2010). Therefore, this set of molecules in the nucleus acts as a DNA degradation complex and is required for large-scale DNA fragmentation and chromatinolysis, which ultimately leads to cell death in a caspase-independent manner. Chromatinolysis mediated by H2AX has also been observed in caspase-dependent apoptosis, in which the DNA degradation is of a different nature, and this could be because of the different actors implicated: caspase 3/caspase-activated DNase or AIF/CypA, respectively (Artus et al., 2010). There is some controversy regarding how the interaction between AIF and CypA enables their translocation to the nucleus (Doti and Ruvo, 2017). One model suggests the independent translocation of both proteins prior to chromatinolysis and DNA fragmentation, and this is supported by the results in a necrosis model in which CypA down-regulation did not compromise the nuclear translocation of AIF but did reduce the extent of DNA damage (Artus et al., 2010). The other model proposes that, upon apoptotic stimuli, AIF and CypA form a complex in the cytosol, and this interaction allows both proteins to translocate to the nucleus and induce cell death (Cande et al., 2004; Zhu et al., 2007a; Doti et al., 2014; [Figure 2]).{Figure 2}

Apoptosis-inducing factor isoforms

Recent studies have shown the existence of more variants of AIF [Figure 1]. AIF2 contains 609 AAs (608 AAs in mice), and it expresses an alternative exon (2b) compared to the other isoform (Loeffler et al., 2001). In opposition to AIF1 (which is ubiquitously expressed), AIF2 is only expressed in the brain (Hangen et al., 2010b). It has been shown that AIF2 is also found in the IMM, but as a result of the alternative splicing of exon 2 (which introduces a short difference in the second MLS of the protein), the segment that is used to anchor the protein into the IMM does so more firmly due to changes in the hydrophobicity of the AAs compared to the other isoform (Hangen et al., 2010b). AIF has been shown to be a major contributor to caspase-independent neuronal loss induced by neonatal cerebral HI, and the Harlequin (Hq) mice, which have an 80% reduction in the expression of the protein (including both isoforms AIF1 and AIF2), showed an impressive reduction of brain injury after HI (Zhu et al., 2007b). However, the brain-specific isoform AIF2 has barely been studied. Previously, one of the few studies on AIF2 showed that, in humans, the mRNA expression of AIFM2 was higher in the adult brain than in the fetal brain, while the mRNA expression of AIF1 was lower (Hangen et al., 2010b). As explained before, the AIF2 isoform is only expressed in the brain, but Hangen and colleagues showed that its distribution is not homogeneous. Approximately 25% of the cells present in the anterior olfactory nucleus stained uniquely for the exon 2b-specific probe, indicating the existence of brain cells that express AIF2 but not AIF1. In that paper, it was also mentioned that AIF2 was more difficult to dissociate from the mitochondrial membrane than AIF1 due to the changes in the AA sequences that affect the region of the protein that is anchored in the IMM, suggesting that AIF2 might contribute less efficiently to apoptosis than AIF1 (Hangen et al., 2010b). AIF has the ability to form dimers or higher-order oligomers, and these complexes can potentially be formed by both AIF1 and/or AIF2 isoforms. Upon apoptotic stimuli, the heterodimers or hetero-oligomers containing one or more AIF2 isoforms would be less likely to be released into the cytosol. Therefore, the AIF1/AIF2 ratio in the IMM might be crucial for the pro-apoptotic role of AIF.

The results in a recent Aif2 knock out (KO) study (Rodriguez et al., 2018) showed that by eliminating the expression of AIF2, AIF1 will increase its expression under physiological conditions by 38% in 9-day-old mice and by 90% in 60-day-old mice as a compensatory reaction. This increase together with the fact that the AIF2 isoform is not expressed, increases the AIF1/AIF2 ratio substantially. In the wild-type mice from this study, under physiological conditions, a natural increase in Aif2 mRNA expression with age (64% higher) was observed, while Aif1 expression remained stable (Rodriguez et al., 2018). AIF is essential for embryonic development, and without it, the programmed cell death necessary during cavitation of embryoid bodies does not occur (Joza et al., 2001). While Aif KO mice are embryonically lethal, Hq mice are viable but display severe phenotypes (Klein et al., 2002). However, in the Aif2 KO study, it was found that AIF2 was not essential for mouse viability, and no phenotype was observed in Aif2 KO adult mice under physiological conditions, except an increase of neurogenesis in the sub-granular zone of the dentate gyrus of the hippocampus in 60-day-old mice (Rodriguez et al., 2018). Interestingly, Hq mice showed progressive loss of adult cerebellar and retinal neurons, and in experiments with Aif KO embryos, the mutant mice had midbrain defects and dramatic deficits in cerebellar Purkinje and granule cell precursors (Ishimura et al., 2008). Aif KO mice displayed greater brain injury at 72 hours after HI, which was attributed to an increase in the expression level of AIF1 when Aifm2 was knocked out. This induced a change in the AIF1/AIF2 ratio that promoted increased oxidative stress and subsequent brain injury after HI (Rodriguez et al., 2018).

Other types of AIF isoforms have also been discovered. AIFsh is produced from an alternative origin of transcription located at intron 9 of the AIF gene. As a result, AIFsh contains the C-terminal AIF domain encoded by exons 10 to 16, lacking MLS, and therefore cannot translocate to the mitochondria. AIFsh is a cytosolic protein that causes the same apoptotic effects as AIF1 but lacks oxidoreductase function. AIFsh is ubiquitously expressed (like AIF1), but a different expression pattern was observed through the tissues between AIF1 and AIFsh (Delettre et al., 2006a). Two other human isoforms have also been discovered: AIFsh2 and AIFsh3 (Delettre et al., 2006b), which are generated by alternative splicing of the exon 9b. AIFsh2 contains AAs 1–324, while AIFsh3 is formed by AAs 87–324, meaning that both lack the C-terminal and NLS2 domains; therefore, they are not translocated to the nucleus (and they both lack the proapoptotic function of AIF). In addition, AIFsh3 also lacks the MLS sequence due to the splicing of exon 2; therefore, the protein is not translocated to the mitochondria [Figure 1]. Interestingly, AIFsh2 is absent in brain tissue (Delettre et al., 2006b).

Importance of apoptosis-inducing factor in perinatal hypoxic-ischemic encephalopathy

The importance of AIF in neuronal cell death after HI was first noticed by using wide spectrum caspase inhibitor, which did not affect AIF release and DNA damage. Furthermore, the number of AIF-positive nuclei was positively correlated with brain injury (Zhu et al., 2003). This was further confirmed by using 9-day-old Hq mice, in which the level of expression of Aif was drastically reduced to 20% of the levels found in wild-type (WT) mice (Zhu et al., 2007b). Hq mice were originally observed to undergo ataxia due to cerebellar atrophy and blindness due to retinal degeneration (Klein et al., 2002). In Hq mice exposed to HI insult, the infarct volume after HI was reduced by 53% in male (YXHq) mice and by 43% in female (XHqXHq) mice. This also confirmed the independence of AIF from the caspase-dependent apoptosis pathway, because the Hq mutation did not inhibit the release of Cyt c after HI, nor the activation of caspase 3, even though Hq mice displayed half the injury severity compared to WT mice. Furthermore, the combined protective effect of the Hq mutation, together with the administration of a caspase inhibition, reduced the infarct volume more than 75%, showing that AIF and caspase act in parallel (Zhu et al., 2007b). Hq mouse neurons were found to be particularly sensitive to oxidative stress-induced cell death, which suggested that AIF indeed acts as a mitochondrial scavenger of reactive oxygen species and/or that AIF is involved in OxPhos. Neonatal Hq mice also exhibited 18% less respiratory chain complex I and 30% less catalase compared with WT mice. Finally, when the Hq mice were administrated an anti-oxidant agent (edaravone), the infarct volume was even more reduced compared to the reduction seen in Hq mice alone (~75% reduction vs. ~50% reduction) and was much more reduced than when edaravone was administrated to WT mice (~20% reduction in infarct volume). This was attributed to the fact that edaravone restored the anti-oxidant defense compromised by the Hq mutation (Zhu et al., 2007b).

Our recent study, by using overexpressing AIF1 transgenic mice (without affecting the expression of AIF2), showed increased brain injury after HI compared to WT littermates (Li et al., 2020). Similar to the results shown in the AIF2 KO study (Rodriguez et al., 2018), under physiological conditions, the overexpression of Aif1 also promoted neurogenesis in the sub-granular zone of the dentate gyrus in adult mice, with no other phenotypic changes. Both studies led us to believe that the increase in the expression of AIF1 (either by knocking out Aif2 or by knocking in a pro-viral insertion of Aif1) was behind this observed neurogenesis.

Regulation of apoptosis-inducing factor

Protein interaction: The AIF switch from a pro-survival to a pro-apoptotic protein is controlled by different mechanisms. The first mechanism involves MOMP, which is regulated by several proteins and serves as a good example of how the caspase-dependent and caspase-independent pathways are related to each other. The extrinsic pathway activates caspase 8, which in turn can activate the protein BID, that, as mentioned before, will lead to the MOMP and pore formation. As a consequence, cell death-related proteins will be released to the cytosol, belonging to both caspase-dependent and caspase-independent pathways (Green and Llambi, 2015). Second, AIF is regulated by the activation of calpain and cathepsin proteases, which are needed to cleave AIF from the IMM (Polster et al., 2005; Cao et al., 2007). Third, AIF’s apoptotic function is controlled by the HSP70 chaperone, which can neutralize AIF by binding to the specific HSP70-binding domain located in AAs 150–228 of mature AIF (Ravagnan et al., 2001). Lastly, AIF is also regulated by poly (ADP-ribose) polymerase 1 (PARP-1), which is a nuclear enzyme involved in DNA repair, by producing poly-ADP ribose polymers using NAD+ However, in case of excessive DNA damage caused by severe genomic stress, overactivation of PARP-1 can drain the cellular NAD+ supply and cause energy depletion (Gill and Perez-Polo, 2008). PARP-1 has been suggested to be a key contributor to cell death, and indeed, the term parthanatos is being used now to refer to the caspase-independent apoptotic pathway based on the overactivation of PARP-1 and consequent NAD+ depletion (David et al., 2009). In addition, PARP-1 overactivation participates in the translocation of AIF from the mitochondria to the nucleus, and in a PARP-1 KO study in mice, neurons failed to release AIF to the nucleus in response to apoptotic stimuli (Yu et al., 2002; [Figure 2]).

It has been established that AIF’s pro-survival function requires a functional coiled-coil-helix-coiled-coil-helix domain-containing protein 4 (CHCHD4) protein, and Aif depletion is correlated with decreased levels of CHCHD4 protein (without affecting mRNA transcription) (Hangen et al., 2015). Furthermore, high levels of CHCHD4 protein have been shown to help offset the problems associated with low levels of AIF, and low levels of CHCHD4 protein have also been shown to lead to similar problems as low levels of AIF (Hangen et al., 2015; Meyer et al., 2015). All of these results suggest that both proteins work epistatically, at least in terms of mitochondrial regulation. In a Chchd4-happloinsufficiency study (Sun et al., 2017), it was shown that reducing the protein expression of the Chchd4 gene by 25% reduced brain damage in 9-day-old mice after HI but did not affect AIF protein expression, suggesting that CHCHD4 protein acts by blocking the release of AIF from the mitochondria upon apoptotic stimuli (as well as blocking Cyt c release; [Figure 2]).

Other proteins have been suggested to interact with AIF. The thioredoxin system is one major redox system in mammalian cells and cytosolic thioredoxin-1 interacts with AIF in physiological conditions, but this interaction is disrupted under pro-apoptotic oxidative stress conditions. Importantly, AIF-mediated DNA damage was attenuated when the expression of thioredoxin-1 was reduced (Shelar et al., 2015). MIF has also been suggested to interact with cytosolic AIF before both of them are translocated to the nucleus. MIF would act as an endonuclease that contributes to large DNA fragmentation induced by PARP-1 (Wang et al., 2016). Lastly, a cytosolic interaction between AIF and receptor-interacting protein 3 in neuronal programmed necrosis has been proposed, with their subsequent translocation to the nucleus inducing necroptosis (Xu et al., 2016). The breakthrough discoveries about AIF have been summarized in a timeline from the first evidence of AIF in 1996 until now [Figure 3].{Figure 3}

Oxidative stress: Free radicals are formed in the brain as a consequence of the HI insult and reperfusion process, and they are implicated in the development of perinatal brain injury (Bågenholm et al., 1997; Ferriero, 2001; Wang et al., 2007). The excessive production of free radicals will lead to oxidative stress that will affect different macromolecules, including lipids, proteins, and nucleic acids (Li et al., 2019). The accumulation of free radicals plays an important role in apoptosis, by modulating mitochondrial permeabilization, and the release of mitochondrial intermembrane pro-apoptotic proteins to the cytosol (Galluzzi et al., 2009; Hagberg et al., 2014). Mitochondria, especially mitochondria in brain cells, are also crucial in the development of oxidative stress, because their energy demands are high. Thus, they are a major source of free radical production (Schönfeld and Reiser, 2013). The consequences of such stress will negatively affect the metabolic processes taking place in mitochondria, leading to a decrease in ATP production (Sun et al., 2016).

AIF also plays a crucial role in mitochondrial energetic functionality, especially with regard to the maintenance of electron transport chain complexes I and III during OxPhos (Öxler et al., 2012). The AIF oxidase-reductase activity was suggested by in vitro experiments performed using natural AIF purified from mitochondria that exhibited NADH oxidase activity (Miramar et al., 2001; Hong et al., 2015). This activity was shown to be independent from its role in apoptosis because of a recombinant AIF form lacking the FAD domain; therefore, its NADH oxidase activity did not lose its apoptotic function (Miramar et al., 2001). In addition, the AIFsh isoform showed apoptotic activity, despite lacking oxide-reductase activity (Delettre et al., 2006a), while AIFsh2 retained oxide-reductase activity, despite lacking apoptotic activity (Delettre et al., 2006b). A similar experiment was replicated some years later, suggesting that AIF is a redox-signaling molecule in which its pro-survival and its pro-apoptotic roles are controlled by NADH (Churbanova and Sevrioukova, 2008). Furthermore, it was pointed out that NAD+ reduction would cause a transition in AIF protein from a monomeric to a dimeric form; moreover, AIF dimerization could potentially lead to a conformational change in the protein affecting the accessibility of the NLS2 binding domain and DNA binding sites (Sevrioukova, 2009).

This property of AIF to form dimers also plays an important role when it comes to explaining some of the results obtained in Aif2 KO study (Hangen et al., 2010b; Rodriguez et al., 2018). The hypothesis behind this is based on the potential capability of AIF2 to be anchored more deeply into the IMM, and because AIF1 and AIF2 can form monomers or dimers (including heterodimers of AIF1/AIF2), AIF2 might have the ability to “kidnap” AIF1 by forming heterodimers, thereby affecting its capacity to translocate from the mitochondria to the cytosol, as well as its oxidoreductase activity. Under apoptotic conditions, there is usually a decrease in the mitochondrial levels of NADH. The fact that these transitional forms (monomers or dimers) are related to the oxidative stress might explain an evolutionary way to regulate the dual function of AIF during the first embryonic stages in the brain. All of this would indicate that the apoptotic function of AIF can be modulated by changes in NADH levels (Churbanova and Sevrioukova, 2008; Sevrioukova, 2009, 2011; Shetty et al., 2014). AIF is a free radical scavenger, and the deficiency of AIF in Hq mouse brain resulted in hydroperoxides in the brain and thus aggravates oxidative stress (Klein et al., 2002; Zhu et al., 2007b). Aif2 KO mice showed higher levels of markers of oxidative stress (Rodriguez et al., 2018). This suggests that local redox equilibria are affected by the changes in the AIF1/AIF2 ratio, which are caused either by the lack of AIF2 or overabundance of AIF1. However, the role of the AIF2 isoform in redox reactions is still unknown. Aifm2 KO mice showed greater severity of brain damage as measured by the infarction area 72 hours after HI, while translocation to the nuclei was similar in Aifm2 KO mice compared to WT mice. Therefore, the most plausible explanation for the increase in the injury severity would be the increased oxidative stress in the KO mice, which might be caused by the difference in the AIF1/AIF2 ratio. Although requiring further study, AIF2 might be a better free radical scavenger than AIF1, and AIF1 and AIF2 differ in their roles in the neonatal brain after HI.

 Sex Differences

Sex differences in perinatal brain damage have been previously reported in different studies (Nijboer et al., 2007; Zhu et al., 2013; Netto et al., 2017; Rodríguez-Fanjul et al., 2017; Charriaut-Marlangue et al., 2018). Based on the analysis of the cell death mechanisms, it has been shown that, AIF, the key to the caspase-independent pathway of cell death is more predominant in males and, in contrast, the caspase-dependent pathway is more prevalent in females (Zhu et al., 2006; Hangen et al., 2015). Both in vitro and in vivo experiments showed that AIF-related sex differences are not because of total AIF protein expression difference, rather AIF release from the mitochondria and translocate to the nucleus after insults. There is somewhat more pronounced AIF release in males than in females (Du et al., 2004; Zhu et al., 2006). As mentioned before, PARP-1 is a nuclear enzyme involved in DNA repair, but it is also involved in a unique PARP-1-dependent cell death program when the DNA damage is severe (Hong et al., 2004). It is closely linked to AIF during the apoptotic process after acute neurological insults (Yu et al., 2002). Previous study has shown that the KO Parp-1 provided significant protection overall in the group of mice. However, analysis by sex revealed that males were strongly protected in contrast to females, in which there was no significant effect. This indicates that the AIF-PARP1 pathway plays an important role in mediating neuronal cell death and sex-related differences in brain injury (Hagberg et al., 2004). Sex differences have also been reported for therapeutic hypothermia (TH), resulting in more effective long-term protection in female than in male 7-day-old rats (Bona et al., 1998; Fan et al., 2013). The sheep asphyxia model found that males showed an increased rate of terminal hypotension, which was not seen in females (Bennet et al., 2007). Clinical study has shown the sex-related differences of erythropoietin on neonatal HIE, with more pronounced protection in the females (Zhu et al., 2009a). All of the above sex differences indicate a “male disadvantage”; thus, the sex should be considered for the therapeutic selection. AIF could be a target for the prevention of brain injury, since AIF plays a more prominent role in neuronal cell death in males.

 Potential Therapeutic Targets

Nowadays, the most common treatment for infants with HIE is based on TH applied within the first 6–10 hours after HI (Tagin et al., 2012; Douglas-Escobar and Weiss, 2015). This treatment has shown that HI brain injury can be mitigated by reducing the risk to approximately 50% (Edwards et al., 2010). However, TH is not a suitable treatment for preterm infants (Barrett et al., 2007), and it has also failed as a therapeutic strategy for severely affected children (Azzopardi et al., 2009). Furthermore, TH does not provide full neuroprotection, and about 40–50% of neonates with moderate to severe HIE still suffer severe neurological complications or die after TH (Edwards et al., 2010).

One option suggested to improve the outcome of HIE patients is to use TH together with other pharmacological adjuvants to increase neuroprotection and/or to promote neural regeneration. In this respect, low doses of recombinant human erythropoietin have shown positive effects in the long-term outcomes for infants with moderate (but not severe) HIE (Juul, 2013; Traudt et al., 2013), with only minor side effects observed (Zhu et al., 2009b). Erythropoietin has been shown to have anti-inflammatory, anti-excitotoxic, anti-oxidative, and anti-apoptotic properties (Villa et al., 2003; Wang et al., 2004). Apart from TH and erythropoietin, other substances have been proposed for improving HIE outcomes (Dixon et al., 2015), including melatonin, which has anti-apoptotic, anti-inflammatory, and anti-oxidative properties (Welin et al., 2007; Alonso-Alconada et al., 2013). Xenon, allopurinol, and magnesium sulfate have also been found to be promising for HIE treatment, but further large sample clinical studies are needed (Cilio and Ferriero, 2010; Yıldız et al., 2017).

Since the discovery that CypA participates in the nuclear translocation of AIF (Zhu et al., 2007a), it has been suggested to be a target for inhibiting AIF translocation after HI. A recent study showed that the AIF/CypA complex presents a good target for generating pharmacological inhibitors that block the cell death process (Thornton et al., 2017). Before that, some studies showed alternatives for that aim, such as targeting the anti-apoptotic BCL-2 family proteins (Yin et al., 2006) or preventing the translocation of AIF to the nucleus by overexpressing HSP70 (Matsumori et al., 2005). Cyclophilins influence the conformation of proteins in cells, among other functions (Kumari et al., 2013). CypA is an abundant, ubiquitously expressed protein, and it is particularly highly expressed in neurons (Göldner and Patrick, 1996). In healthy neurons, CypA is localized both in the cytoplasm and nuclei, and it is not essential for mammalian cell viability, as indicated by the fact that CypA KO embryonic stem cells grow normally and differentiate into hematopoietic precursor cells in vitro (Colgan et al., 2000). It has been shown that a CypA KO study reduced the total infarct volume by 46.7% and total tissue loss by 33.8% compared to the WT littermates after HI, without affecting the mitochondrial release of cell death effectors (Zhu et al., 2007a). A peptide based on the AIF and CypA sequences that corresponds to the surfaces involved in binding has already been designed (AIF370–394). This molecule acts as a cell-penetrating peptide by using the trans-activator of transcription sequence (GRKKRRQRRRPQ), which has been a very successful way to overcome the lipophilic barrier of the cellular membranes and to deliver molecules inside the cell (Vives et al., 1997; Brooks et al., 2005). In vitro experiments in a model of glutamate-induced oxidative stress in cultured HT-22 cells have already demonstrated the efficacy and protective effect of the peptide, by acting as a competitive inhibitor of the AIF/CypA complex formation, and therefore blocking its subsequent translocation to the nucleus (Doti et al., 2014). The peptide AIF370–394 exerted pronounced neuroprotective effects while preserving its mitochondrial integrity. The effect of this peptide in a mouse HI model confirms the AIF/CypA complex as an excellent therapeutic target for preventing perinatal brain injury (unpublished data).

AIF1 has shown to be important not only for neonatal HIE but also for other organs, as the expression of AIF1 is low in the brain compared to other organs (Hangen et al., 2010b). AIF release from the mitochondria was observed in cardiomyocytes after heart failure and ischemia/reperfusion injury (Siu et al., 2007). Interestingly, muscle-specific AIF KO mice developed skeletal muscle atrophy and cardiomyopathy secondary to complex I deficiency (Joza et al., 2005; Bano and Prehn, 2018). Therefore, therapeutic strategies targeting AIF could potentially go beyond neuroprotection.


The mechanisms of perinatal brain injury are not fully understood, but AIF plays a prominent role, not only due to its central function in the maintenance of mitochondrial function and oxidative levels but also because it is the key protein involved in cell death in a caspase-independent manner. AIF has already been shown to make important contributions to neuronal cell death upon HI in the immature brain. A better understanding of the mechanisms behind these processes, including the role of all AIF isoforms, and their interactions with other proteins, are needed for the development of improved and more effective treatments during the early stages of perinatal brain injury.

Author contributions: JR, TL, YX and YS wrote the original draft. CZ conceptualized, designed, reviewed and edited the review. All authors approved the final manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: This work was supported by the Swedish Research Council (2018-02667), the National Natural Science Foundation of China (31761133015, U1704281, 81901335), the Swedish Childhood Cancer Foundation (PR2018-0082), Swedish Governmental Grants to Scientists Working in Health Care (ALFGBG-717791), the Swedish Brain Foundation (FO2018-0034 and the Chinese Scholarship Council to TL (201707040025) and to YX (201507040082).

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open peer reviewer: N. Scott Litofsky, University of Missouri School of Medicine, USA.

Funding: This work was supported by the Swedish Research Council (2018-02667), the National Natural Science Foundation of China (31761133015, U1704281, 81901335), the Swedish Childhood Cancer Foundation (PR2018-0082), Swedish Governmental Grants to Scientists Working in Health Care (ALFGBG-717791), the Swedish Brain Foundation (FO2018-0034) and the Chinese Scholarship Council to TL (201707040025) and to YX (201507040082).


1Alonso-Alconada D, Álvarez A, Arteaga O, Martínez-Ibargüen A, Hilario E (2013) Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J Mol Sci 14:9379-9395.
2Artus C, Boujrad H, Bouharrour A, Brunelle MN, Hoos S, Yuste VJ, Lenormand P, Rousselle JC, Namane A, England P (2010) AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J 29:1585-1599.
3Azzopardi D, Robertson NJ, Bainbridge A, Cady E, Charles-Edwards G, Deierl A, Fagiolo G, Franks NP, Griffiths J, Hajnal J, Juszczak E, Kapetanakis B, Linsell L, Maze M, Omar O, Strohm B, Tusor N, Edwards AD (2016) Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol 15:145-153.
4Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E (2009) Moderate hypothermia to treat perinatal asphyxial encephalopathy. New Engl J Med 361:1349-1358.
5Bågenholm R, Nilsson UA, Kjellmer I (1997) Formation of free radicals in hypoxic ischemic brain damage in the neonatal rat, assessed by an endogenous spin trap and lipid peroxidation. Brain Res 773:132-138.
6Bano D, Prehn JH (2018) Apoptosis-inducing factor (AIF) in physiology and disease: the tale of a repented natural born killer. EBioMedicine 30:29-37.
7Barrett RD, Bennet L, Davidson J, Dean JM, George S, Emerald BS, Gunn AJ (2007) Destruction and reconstruction: hypoxia and the developing brain. Birth Defects Res C Embryo Today 81:163-176.
8Bennet L, Booth LC, Ahmed-Nasef N, Dean JM, Davidson J, Quaedackers JS, Gunn AJ (2007) Male disadvantage? Fetal sex and cardiovascular responses to asphyxia in preterm fetal sheep. Am J Physiol Regul Integr Comp Physiol 293:R1280-1286.
9Bennet L, Van Den Heuij L, M Dean J, Drury P, Wassink G, Jan Gunn A (2013) Neural plasticity and the K ennard principle: does it work for the preterm brain? Clin Exp Pharmacol Physiol 40:774-784.
10Bona E, Hagberg H, Løberg EM, Bågenholm R, Thoresen M (1998) Protective effects of moderate hypothermia after neonatal hypoxia-ischemia: short-and long-term outcome. Pediatric Res 43:738.
11Brooks H, Lebleu B, Vivès E (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57:559-577.
12Cande C, Vahsen N, Kouranti I, Schmitt E, Daugas E, Spahr C, Luban J, Kroemer RT, Giordanetto F, Garrido C (2004) AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene 23:1514.
13Candé C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N, Kroemer G (2002) Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 84:215-222.
14Cao G, Xing J, Xiao X, Liou AK, Gao Y, Yin XM, Clark RS, Graham SH, Chen J (2007) Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 27:9278-9293.
15Carli G, Reiger I, Evans N (2004) One-year neurodevelopmental outcome after moderate newborn hypoxic ischaemic encephalopathy. J Paediatr Child Health 40:217-220.
16Charriaut-Marlangue C, Besson V, Baud O (2018) Sexually dimorphic outcomes after neonatal stroke and hypoxia-ischemia. Int J Mol Sci 19:61.
17Churbanova IY, Sevrioukova IF (2008) Redox-dependent changes in molecular properties of mitochondrial apoptosis-inducing factor. J Biol Chem 283:5622-5631.
18Cilio MR, Ferriero DM (2010) Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med 15:293-298.
19Colgan J, Asmal M, Luban J (2000) Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability. Genomics 68:167-178.
20David KK, Andrabi SA, Dawson TM, Dawson VL (2009) Parthanatos, a messenger of death. Front Biosci (Landmark Edit) 14:1116.
21Delettre C, Yuste VJ, Moubarak RS, Bras M, Lesbordes-Brion JC, Petres S, Bellalou J, Susin SA (2006a) AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer. J Biol Chem 281:6413-6427.
22Delettre C, Yuste VJ, Moubarak RS, Bras M, Robert N, Susin SA (2006b) Identification and characterization of AIFsh2, a mitochondrial apoptosis-inducing factor (AIF) isoform with NADH oxidase activity. J Biol Chem 281:18507-18518.
23Demarest TG, Schuh RA, Waddell J, McKenna MC, Fiskum G (2016) Sex-dependent mitochondrial respiratory impairment and oxidative stress in a rat model of neonatal hypoxic-ischemic encephalopathy. J Neurochem 137:714-729.
24Dixon B, Reis C, Ho W, Tang J, Zhang J (2015) Neuroprotective strategies after neonatal hypoxic ischemic encephalopathy. Int J Mol Sci 16:22368-22401.
25Doti N, Reuther C, Scognamiglio P, Dolga A, Plesnila N, Ruvo M, Culmsee C (2014) Inhibition of the AIF/CypA complex protects against intrinsic death pathways induced by oxidative stress. Cell Death Dis 5:e993.
26Doti N, Ruvo M (2017) Relevance and therapeutic potential of CypA targeting to block apoptosis inducing factor-mediated neuronal cell death. Neural Regen Res 12:1428-1429.
27Douglas-Escobar M, Weiss MD (2015) Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatr 169:397-403.
28Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC, Graham SH, Clark RS (2004) Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 279:38563-38570.
29Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D (2010) Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 340:c363.
30Elguindy MM, Nakamaru-Ogiso E (2015) Apoptosis-inducing factor (AIF) and its family member protein, AMID, are rotenone-sensitive NADH: ubiquinone oxidoreductases (NDH-2). J Biol Chem 290:20815-20826.
31Fan X, Van Bel F, Van Der Kooij MA, Heijnen CJ, Groenendaal F (2013) Hypothermia and erythropoietin for neuroprotection after neonatal brain damage. Pediatr Res 73:18-23.
32Fato R, Bergamini C, Leoni S, Strocchi P, Lenaz G (2008) Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res 33:2487-2501.
33Fatokun AA, Dawson VL, Dawson TM (2014) Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171:2000-2016.
34Ferriero DM (2001) Oxidant mechanisms in neonatal hypoxia-ischemia. Dev Neurosci 23:198-202.
35Galinsky R, Lear CA, Dean JM, Wassink G, Dhillon SK, Fraser M, Davidson JO, Bennet L, Gunn AJ (2018) Complex interactions between hypoxia-ischemia and inflammation in preterm brain injury. Dev Med Child Neurol 60:126-133.
36Galluzzi L, Blomgren K, Kroemer G (2009) Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 10:481-494.
37Gill MB, Perez-Polo JR (2008) Hypoxia ischemia-mediated cell death in neonatal rat brain. Neurochem Res 33:2379-2389.
38Göldner FM, Patrick JW (1996) Neuronal localization of the cyclophilin A protein in the adult rat brain. J Comp Neurol 372:283-293.
39Gopagondanahalli KR, Li J, Fahey MC, Hunt RW, Jenkin G, Miller SL, Malhotra A (2016) Preterm hypoxic–ischemic encephalopathy. Front Pediatr 4:114.
40Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7:a006080.
41Hagberg H, David Edwards A, Groenendaal F (2016) Perinatal brain damage: The term infant. Neurobiol Dis 92:102-112.
42Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW, Vexler ZS, Gressens P (2015) The role of inflammation in perinatal brain injury. Nat Rev Neurol 11:192-208.
43Hagberg H, Mallard C, Rousset CI, Thornton C (2014) Mitochondria: hub of injury responses in the developing brain. Lancet Neurol 13:217-232.
44Hagberg H, Wilson MA, Matsushita H, Zhu C, Lange M, Gustavsson M, Poitras MF, Dawson TM, Dawson VL, Northington F, Johnston MV (2004) PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90:1068-1075.
45Hangen E, Blomgren K, Bénit P, Kroemer G, Modjtahedi N (2010a) Life with or without AIF. Trends Biochem Sci 35:278-287.
46Hangen E, De Zio D, Bordi M, Zhu C, Dessen P, Caffin F, Lachkar S, Perfettini J-L, Lazar V, Benard J (2010b) A brain-specific isoform of mitochondrial apoptosis-inducing factor: AIF2. Cell Death Differ 17:1155-1166.
47Hangen E, Féraud O, Lachkar S, Mou H, Doti N, Fimia GM, Lam N-v, Zhu C, Godin I, Muller K (2015) Interaction between AIF and CHCHD4 regulates respiratory chain biogenesis. Mol Cell 58:1001-1014.
48Hankins GD, Speer M (2003) Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstet Gynecol 102:628-636.
49Hayakawa M, Ito Y, Saito S, Mitsuda N, Hosono S, Yoda H, Cho K, Otsuki K, Ibara S, Terui K (2014) Incidence and prediction of outcome in hypoxic–ischemic encephalopathy in Japan. Pediatr Int 56:215-221.
50Hong SJ, Dawson TM, Dawson VL (2004) Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 25:259-264.
51Hong Y, Nie H, Wei X, Fu S, Ying W (2015) NAD+ treatment can prevent rotenone-induced increases in DNA damage, Bax levels and nuclear translocation of apoptosis-inducing factor in differentiated PC12 cells. Neurochem Res 40:837-842.
52Hua C, Ju WN, Jin H, Sun X, Zhao G (2017) Molecular chaperones and hypoxic-ischemic encephalopathy. Neural Regen Res 12:153-160.
53Ishimura R, Martin GR, Ackerman SL (2008) Loss of apoptosis-inducing factor results in cell-type-specific neurogenesis defects. J Neurosci 28:4938-4948.
54Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273:9357-9360.
55Joza N, Oudit GY, Brown D, Bénit P, Kassiri Z, Vahsen N, Benoit L, Patel MM, Nowikovsky K, Vassault A (2005) Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol Cell Biol 25:10261-10272.
56Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, Cheng H-YM, Ravagnan L (2001) Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410:549.
57Juul SE, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, Robinson T, Ahmad KA, Bendel-Stenzel E, Baserga M, LaGamma EF, Downey LC, Rao R, Fahim N, Lampland A, Frantz Iii ID, Khan JY, Weiss M, Gilmore MM, Ohls RK, Srinivasan N, et al. (2020) A randomized trial of erythropoietin for neuroprotection in preterm infants. N Engl J Med 382:233-243.
58Juul SE (2013) Hypothermia plus erythropoietin for neonatal neuroprotection? Commentary on Fan et al. and Fang et al. Pediatr Res 73:10-11.
59Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT, Ackerman SL (2002) The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419:367.
60Korsmeyer S, Wei M, Saito M, Weiler S, Oh K, Schlesinger P (2000) Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7:1166-1173.
61Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99-163.
62Kumari S, Roy S, Singh P, Singla-Pareek S, Pareek A (2013) Cyclophilins: proteins in search of function. Plant Signal Behav 8:e22734.
63Lally PJ, Montaldo P, Oliveira V, Soe A, Swamy R, Bassett P, Mendoza J, Atreja G, Kariholu U, Pattnayak S, Sashikumar P, Harizaj H, Mitchell M, Ganesh V, Harigopal S, Dixon J, English P, Clarke P, Muthukumar P, Satodia P, et al. (2019) Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. Lancet Neurol 18:35-45.
64Li K, Li T, Wang Y, Xu Y, Zhang S, Culmsee C, Wang X, Zhu C (2019) Sex differences in neonatal mouse brain injury after hypoxia-ischemia and adaptaquin treatment. J Neurochem 150:759-775.
65Li T, Li K, Zhang S, Wang Y, Xu Y, Cronin SJ, Sun Y, Zhang Y, Xie C, Rodriguez J (2020) Overexpression of apoptosis inducing factor aggravates hypoxic-ischemic brain injury in neonatal mice. Cell Death Dis 11:1-18.
66Lindström K, Lagerroos P, Gillberg C, Fernell E (2006) Teenage outcome after being born at term with moderate neonatal encephalopathy. Pediatr Neurol 35:268-274.
67Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE (2016) Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the sustainable development goals. Lancet 388:3027-3035.
68Loeffler M, Daugas E, Susin SA, Zamzami N, Métivier D, Nieminen A-L, Brothers G, Penninger JM, Kroemer G (2001) Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J 15:758-767.
69Lorenzo HK, Susin SA, Penninger J, Kroemer G (1999) Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 6:516-524.
70Matsumori Y, Hong SM, Aoyama K, Fan Y, Kayama T, Sheldon RA, Vexler ZS, Ferriero DM, Weinstein PR, Liu J (2005) Hsp70 overexpression sequesters AIF and reduces neonatal hypoxic/ischemic brain injury. J Cereb Blood Flow Metab 25:899-910.
71Meyer K, Buettner S, Ghezzi D, Zeviani M, Bano D, Nicotera P (2015) Loss of apoptosis-inducing factor critically affects MIA40 function. Cell Death Dis 6:e1814.
72Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G, Susin SA (2001) NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem 276:16391-16398.
73Natarajan G, Pappas A, Shankaran S (2016) Outcomes in childhood following therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy (HIE). Semin Perinatol 40:549-555.
74Netto CA, Sanches E, Odorcyk FK, Duran-Carabali LE, Weis SN (2017) Sex-dependent consequences of neonatal brain hypoxia-ischemia in the rat. J Neurosci Res 95:409-421.
75Nijboer CH, Groenendaal F, Kavelaars A, Hagberg HH, van Bel F, Heijnen CJ (2007) Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J Cereb Blood Flow Metab 27:282-292.
76Otera H, Ohsakaya S, Nagaura ZI, Ishihara N, Mihara K (2005) Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J 24:1375-1386.
77Öxler E-M, Dolga A, Culmsee C (2012) AIF depletion provides neuroprotection through a preconditioning effect. Apoptosis 17:1027-1038.
78Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM (2000) A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Current Biol 10:886-895.
79Polster BM, Basañez G, Etxebarria A, Hardwick JM, Nicholls DG (2005) Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 280:6447-6454.
80Porter AG, Urbano AG (2006) Does apoptosis-inducing factor (AIF) have both life and death functions in cells? Bioessays 28:834-843.
81Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jäättelä M, Penninger JM, Garrido C (2001) Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3:839.
82Rodriguez J, Zhang Y, Li T, Xie C, Sun Y, Xu Y, Zhou K, Huo K, Wang Y, Wang X, Andersson D, Stahlberg A, Xing Q, Mallard C, Hagberg H, Modjtahedi N, Kroemer G, Blomgren K, Zhu C (2018) Lack of the brain-specific isoform of apoptosis-inducing factor aggravates cerebral damage in a model of neonatal hypoxia-ischemia. Cell Death Dis 10:3.
83Rodríguez-Fanjul J, Fernández-Feijóo CD, Lopez-Abad M, Ramos MGL, Caballe RB, Alcántara-Horillo S, Camprubi MC (2017) Neuroprotection with hypothermia and allopurinol in an animal model of hypoxic-ischemic injury: Is it a gender question? PLoS One 12:e0184643
84Sarnat HB, Sarnat MS (1976) Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. Arch Neurol 33:696-705.
85Schreglmann M, Ground A, Vollmer B, Johnson MJ (2020) Systematic review: long-term cognitive and behavioural outcomes of neonatal hypoxic-ischaemic encephalopathy in children without cerebral palsy. Acta Paediatr 109:20-30.
86Schönfeld P, Reiser G (2013) Why does brain metabolism not favor burning of fatty acids to provide energy?-Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab 33:1493-1499.
87Sevrioukova IF (2009) Redox-linked conformational dynamics in apoptosis-inducing factor. J Mol Biol 390:924-938.
88Sevrioukova IF (2011) Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal 14:2545-2579.
89Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW (2011) BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys Acta 1813:508-520.
90Shelar SB, Kaminska KK, Reddy SA, Kumar D, Tan CT, Victor CY, Lu J, Holmgren A, Hagen T, Chew EH (2015) Thioredoxin-dependent regulation of AIF-mediated DNA damage. Free Radic Biol Med 87:125-136.
91Shetty PK, Galeffi F, Turner DA (2014) Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia. Neurobiol Dis 62:469-478.
92Siu PM, Bae S, Bodyak N, Rigor DL, Kang PM (2007) Response of caspase-independent apoptotic factors to high salt diet-induced heart failure. J Mol Cell Cardiol 42:678-686.
93Stehle D, Grimm M, Einsele-Scholz S, Ladwig F, Johanning J, Fischer G, Gillissen B, Schulze-Osthoff K, Essmann F (2018) Contribution of BH3-domain and transmembrane-domain to the activity and interaction of the pore-forming Bcl-2 proteins Bok, Bak, and Bax. Sci Rep 8:12434.
94Sun Y, Li T, Xie C, Xu Y, Zhou K, Rodriguez J, Han W, Wang X, Kroemer G, Modjtahedi N, Blomgren K, Zhu C (2017) Haploinsufficiency in the mitochondrial protein CHCHD4 reduces brain injury in a mouse model of neonatal hypoxia-ischemia. Cell Death Dis 8:e2781.
95Sun Y, Li T, Xie C, Zhang Y, Zhou K, Wang X, Blomgren K, Zhu C (2016) Dichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal mice. Oncotarget 7:31708-31722.
96Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prévost M-C, Alzari PM, Kroemer G (1999a) Mitochondrial release of caspase-2 and-9 during the apoptotic process. J Exp Med 189:381-394.
97Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M (1999b) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441.
98Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G (1996) Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 184:1331-1341.
99Sutcliffe TC, Winter AN, Punessen NC, Linseman DA (2017) Procyanidin B2 protects neurons from oxidative, nitrosative, and excitotoxic stress. Antioxidants (Basel) doi: 10.3390/antiox6040077.
100Tagin M, Zhu C, Gunn AJ (2015) Beneficence and nonmaleficence in treating neonatal hypoxic-ischemic brain injury. Dev Neurosci 37:305-310.
101Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA (2012) Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 166:558-566.
102Thornton C, Leaw B, Mallard C, Nair S, Jinnai M, Hagberg H (2017) Cell death in the developing brain after hypoxia-ischemia. Front Cell Neurosci 11:248.
103Traudt CM, McPherson RJ, Bauer LA, Richards TL, Burbacher TM, McAdams RM, Juul SE (2013) Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 35:491-503.
104Vahsen N, Candé C, Brière JJ, Bénit P, Joza N, Larochette N, Mastroberardino PG, Pequignot MO, Casares N, Lazar V (2004) AIF deficiency compromises oxidative phosphorylation. EMBO J 23:4679-4689.
105Van Handel M, Swaab H, De Vries LS, Jongmans MJ (2007) Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review. Eur J Pediatr 166:645-654.
106Wajant H (2002) The Fas signaling pathway: more than a paradigm. Science 296:1635-1636.
107Wang L, Zhang Z, Wang Y, Zhang R, Chopp M (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35:1732-1737.
108Wang X, Han W, Du X, Zhu C, Carlsson Y, Mallard C, Jacotot E, Hagberg H (2010) Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. Stroke 41:2050-2055.
109Wang X, Svedin P, Nie C, Lapatto R, Zhu C, Gustavsson M, Sandberg M, Karlsson JO, Romero R, Hagberg H, Mallard C (2007) N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol 61:263-271.
110Wang Y, An R, Umanah GK, Park H, Nambiar K, Eacker SM, Kim B, Bao L, Harraz MM, Chang C (2016) A nuclease that mediates cell death induced by DNA damage and poly (ADP-ribose) polymerase-1. Science 354:aad6872.
111Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, Gressens P, Kjellmer I, Mallard C (2007) Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr Res 61:153-158.
112Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971-975.
113Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017.
114Wu Y, Song J, Wang Y, Wang X, Culmsee C, Zhu C (2019) The Potential role of ferroptosis in neonatal brain injury. Front Neurosci 13:115.
115Xie C, Ginet V, Sun Y, Koike M, Zhou K, Li T, Li H, Li Q, Wang X, Uchiyama Y (2016) Neuroprotection by selective neuronal deletion of Atg7 in neonatal brain injury. Autophagy 12:410-423.
116Xu Y, Wang J, Song X, Qu L, Wei R, He F, Wang K, Luo B (2016) RIP3 induces ischemic neuronal DNA degradation and programmed necrosis in rat via AIF. Sci Rep 6:29362.
117Yıldız EP, Ekici B, Tatlı B (2017) Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert Rev Neurother 17:449-459.
118Yin W, Cao G, Johnnides MJ, Signore AP, Luo Y, Hickey RW, Chen J (2006) TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic–ischemic brain injury via inhibition of caspases and AIF. Neurobiol Dis 21:358-371.
119Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, Dawson TM, Dawson VL (2002) Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259-263.
120Yuste V, Moubarak R, Delettre C, Bras M, Sancho P, Robert N, d’Alayer J, Susin S (2005) Cysteine protease inhibition prevents mitochondrial apoptosis-inducing factor (AIF) release. Cell Death Differ 12:1445-1448.
121Zamzami N, Susin SA, Marchetti P, Hirsch T, Gómez-Monterrey I, Castedo M, Kroemer G (1996) Mitochondrial control of nuclear apoptosis. J Exp Med 183:1533-1544.
122Zhu C, Hallin U, Ozaki Y, Grandér R, Gatzinsky K, Bahr BA, Karlsson J-O, Shibasaki F, Hagberg H, Blomgren K (2010) Nuclear translocation and calpain-dependent reduction of Bcl-2 after neonatal cerebral hypoxia-ischemia. Brain Behav Immun 24:822-830.
123Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G (2009a) Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 124:e218-226.
124Zhu C, Qiu L, Wang X, Hallin U, Candé C, Kroemer G, Hagberg H, Blomgren K (2003) Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemia in the neonatal rat brain. J Neurochem 86:306-317.
125Zhu C, Sun Y, Gao J, Wang X, Plesnila N, Blomgren K (2013) Inhaled nitric oxide protects males but not females from neonatal mouse hypoxia-ischemia brain injury. Transl Stroke Res 4:201-207.
126Zhu C, Wang X, Deinum J, Huang Z, Gao J, Modjtahedi N, Neagu MR, Nilsson M, Eriksson PS, Hagberg H (2007a) Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med 204:1741-1748.
127Zhu C, Wang X, Huang Z, Qiu L, Xu F, Vahsen N, Nilsson M, Eriksson P, Hagberg H, Culmsee C (2007b) Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ 14:775-784.
128Zhu C, Wang X, Xu F, Bahr B, Shibata M, Uchiyama Y, Hagberg H, Blomgren K (2005) The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ 12:162-176.
129Zhu C, Xu F, Wang X, Shibata M, Uchiyama Y, Blomgren K, Hagberg H (2006) Different apoptotic mechanisms are activated in male and female brains after neonatal hypoxia-ischaemia. J Neurochem 96:1016-1027.